We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Loss of CD20 expression following treatment with rituximab (chimaeric monoclonal anti-CD20): a retrospective cohort analysis.
- Authors
Foran, James M.; Norton, andrew J.; Micallef, Ivana N. M.; Taussig, David C.; Amess, John A. L.; Rohatiner, Ama Z. S.; Lister, T. Andrew
- Abstract
A retrospective analysis of CD20 expression following rituximab for B-cell non-Hodgkin's lymphoma demonstrated a significant change in immunophenotype in 6/25 (24%) patients with persistent bone marrow (BM) infiltration. In three out of six patients, the B cells were uniformly CD20-/CD79α+, consistent with frank loss of CD20 expression. In the remaining three cases, the BM infiltrate was predominantly (> 80%) CD20-/CD79α+. Two of the former but none of the latter three cases achieved a clinical response. In three further cases, the post-treatment BM infiltrate was composed entirely of benign or reactive CD3+ T cells. Frank loss of CD20 was not seen in 25 post‐treatment lymph node biopsies. Immunophenotyping is therefore an important adjunct in the diagnosis of BM infiltration following rituximab.
- Subjects
LYMPHOMA treatment; HODGKIN'S disease treatment; BONE marrow diseases; B cells; PHYSIOLOGY
- Publication
British Journal of Haematology, 2001, Vol 114, Issue 4, p881
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1046/j.1365-2141.2001.03019.x